FirstCash Vaults on Financial Position
FirstCash Holdings, Inc. (NASDAQ: FCFS) shares gained first thing Thursday. The Fort Worth-based company, the leading international operator of pawn stores, today announced that it has completed its previously announced acquisition of H&T Group plc H&T is the largest operator of pawn stores in the United Kingdom with 286 locations.The strategic combination with H&T marks another significant milestone for FirstCash, entering the European market for the first time and further enhancing its position as a global leader in the pawn industry with now over 3,300 retail pawn locations and annualized pro forma revenues approaching $4 billion."We are extremely excited to welcome H&T to the FirstCash family," said CEO Rick Wessel. “This transaction aligns perfectly with our mission to further expand FirstCash’s pawn operations and deliver exceptional value to our customers and shareholders. H&T's strong brand reputation, commitment to customer service and growth potential make it an ideal fit with our culture and strategy.“FirstCash believes that H&T’s market-leading position in the U.K. provides premier access to an attractive market, supported by a seasoned management and operations team with the ability to further expand H&T’s operating footprint through store openings and acquisitions in the U.K. Longer-term, we expect the combination of FirstCash and H&T to provide a platform for further international expansion.”FCFS shares popped $1.84, or 1.3%, to $141.11.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


